ES3065770T3 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Info

Publication number
ES3065770T3
ES3065770T3 ES18741939T ES18741939T ES3065770T3 ES 3065770 T3 ES3065770 T3 ES 3065770T3 ES 18741939 T ES18741939 T ES 18741939T ES 18741939 T ES18741939 T ES 18741939T ES 3065770 T3 ES3065770 T3 ES 3065770T3
Authority
ES
Spain
Prior art keywords
interleukin
receptor
inflammatory diseases
peptide inhibitors
treat inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18741939T
Other languages
English (en)
Inventor
Ashok Bhandari
Gregory Bourne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Application granted granted Critical
Publication of ES3065770T3 publication Critical patent/ES3065770T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES18741939T 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Active ES3065770T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447778P 2017-01-18 2017-01-18
PCT/US2018/014257 WO2018136646A1 (en) 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
ES3065770T3 true ES3065770T3 (en) 2026-05-07

Family

ID=62908287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18741939T Active ES3065770T3 (en) 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (7)

Country Link
US (2) US20200207822A1 (es)
EP (1) EP3570864B1 (es)
JP (3) JP2020505352A (es)
AU (1) AU2018210174B2 (es)
CA (1) CA3049889A1 (es)
ES (1) ES3065770T3 (es)
WO (1) WO2018136646A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
MX2022000397A (es) * 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
TW202116793A (zh) * 2019-07-10 2021-05-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
CN118063554A (zh) * 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20220141808A (ko) * 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
AU2022310354A1 (en) * 2021-07-14 2024-02-29 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑
CA3240982A1 (en) 2021-12-01 2023-06-08 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN119487048A (zh) 2022-06-30 2025-02-18 赛诺菲 作为选择性il-23受体拮抗剂的新型肽
JP2025523026A (ja) * 2022-07-14 2025-07-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｌ－２３の環状ペプチド阻害剤
AU2024209094A1 (en) * 2023-01-16 2025-09-04 Janssen Pharmaceutica Nv Formulations of lipidated peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2025051920A1 (en) 2023-09-08 2025-03-13 Sanofi New peptides as selective il-23 receptor inhibitors
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
TW202607011A (zh) 2024-07-12 2026-02-16 丹麥商西蘭製藥公司 介白素－２３受體之胜肽抑制劑
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
UA123772C2 (uk) 2015-07-15 2021-06-02 Протагоніст Терепьютікс, Інк. Пептидний інгібітор рецептора інтерлейкіну-23 та спосіб лікування запального захворювання кишечнику (ibd)
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation

Also Published As

Publication number Publication date
EP3570864A1 (en) 2019-11-27
AU2018210174A1 (en) 2019-07-25
AU2018210174B2 (en) 2022-04-07
JP2025162551A (ja) 2025-10-27
JP2023014346A (ja) 2023-01-26
CA3049889A1 (en) 2018-07-26
EP3570864A4 (en) 2020-12-30
EP3570864B1 (en) 2026-02-18
JP7819087B2 (ja) 2026-02-24
WO2018136646A1 (en) 2018-07-26
US20240132558A1 (en) 2024-04-25
JP2020505352A (ja) 2020-02-20
EP3570864C0 (en) 2026-02-18
US20200207822A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
IL256827A (en) Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases
IL285614A (en) Oral peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory bowel diseases
IL289628A (en) Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases
LT4090670T (lt) Interleukino-23 receptorių peptidiniai inhibitoriai ir jų naudojimas uždegiminėms ligoms gydyti
ZA201906485B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
IL273208A (en) Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases
IL257065A (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
EP3570864A4 (en) PEPTIDES OF INTERLEUKIN-23 RECEPTOR INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL249223A0 (en) Mth1 inhibitors for the treatment of inflammatory and autoimmune conditions
IL310483A (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
IL253796A0 (en) Therapeutically active compounds and methods of use
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL256515A (en) Therapeutic peptides and methods of use thereof
IL271074A (en) Treatment of inflammatory diseases with c5a activity inhibitors
PT3157531T (pt) Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo
ZA202101587B (en) Protein for treatment of inflammatory diseases
SG11202006601VA (en) Methods of treating chronic inflammatory diseases
SG11201708657XA (en) Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
KR102594780B9 (ko) Igfbp-3 및 그것의 수용체와 관련되는 질환의 치료
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
IL252779A0 (en) Prevention and treatment of inflammatory conditions
IL269308A (en) Methods for treating inflammatory diseases associated with HLA-B27 and related preparations
EP3523433C0 (en) MEANS AND METHODS FOR TREATING INFLAMMATORY DISEASES
ZA201700571B (en) Therapeutically active compounds and their methods of use